A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses

Gynecologic Oncology

Volumn 104, Issue 1, 2007, Pages 199-206

  Yan, Qin ^a,b   Cheung, Ying Kit ^a   Chak Sum Cheng, Samuel ^a   Xian Hua, Wang ^a,b   Shi, Meng ^b   Mei Haob, Hu ^c   Yong, Xie ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b PEKING UNIVERSITY   (China)

^c NONE

Author keywords

E6 oncogene; E7 oncogene; Human papillomavirus type 16 (HPV16); Recombinant DNA vaccine; Tumor vaccine

Indexed keywords

DNA VACCINE; PROTEIN E6; PROTEIN E7; RECOMBINANT DNA; RECOMBINANT VACCINE; RETROVIRUS VECTOR; VIRUS DNA; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DOSE COMPARISON; EXPRESSION VECTOR; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS ETIOLOGY; VIRUS GENE;

ANIMALS; ANTIBODIES, VIRAL; BALB 3T3 CELLS; CELL TRANSFORMATION, VIRAL; CERCOPITHECUS AETHIOPS; COS CELLS; DNA, VIRAL; FEMALE; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; PLASMIDS; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINES, DNA;

EID: 33846104270     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.07.044     Document Type: Article

References (34)

1. Jansen K.U., and Shaw A.R. Human papillomavirus vaccines and prevention of cervical cancer. Annu. Rev. Med. 55 (2004) 319-331 [Review]
2. zur Hausen H. Papillomavirus infections-A major cause of human cancers. Biochim. Biophys. Acta 1288 (1996) F55-F78
3. Karube A., Sasaki M., Tanaka H., Nakagome O., Dahiya R., Fujimoto S., et al. Human papilloma virus type 16 infection and the early onset of cervical cancer. Biochem. Biophys. Res. Commun. 323 (2004) 621-624
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer. 2 (2002) 342-350 [Review]
5. Wu T.C. Immunology of the human papilloma virus in relation to cancer. Curr. Opin. Immunol. 6 (1994) 746-754
6. Doel T.R. Optimization of the immune response to foot-and-mouth disease vaccines. Vaccine 17 (1999) 1767-1771
7. Shedlock D.J., and Weiner D.B. DNA vaccination: antigen presentation and the induction of immunity. J. Leukocyte Biol. 68 (2000) 793-806 [Review]
8. Tighe H., Corr M., Roman M., and Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19 (1998) 89-97
9. DiPaolo J.A., and Alvarez-Salas L.M. Advances in the development of therapeutic nucleic acids against cervical cancer. Expert Opin. Biol. Ther. 4 (2004) 1251-1264 [Review]
10. Fazio V.M. "Naked" DNA transfer technology for genetic vaccination against infectious disease. Res. Virol. 148 (1997) 101-108
11. Zarozinski C.C., Fynan E.F., Selin L.K., Robinson H.L., and Welsh R.M. Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein. J. Immunol. 154 (1995) 4010-4017
12. Hosie M.J., Flynn J.N., Rigby M.A., Cannon C., Dunsford T., Mackay N.A., et al. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J. Virol. 72 (1998) 7310-7319
13. Hassett D.E., Zhang J., and Whitton J.L. Plasmid DNA vaccines are effective in the absence of IFNgamma. Virology 263 (1999) 175-183
14. Whitton J.L., Rodriguez F., Zhang J., and Hassett D.E. DNA immunization: mechanistic studies. Vaccine 17 (1999) 1612-1619
15. Hassett D.E., Zhang J., and Whitton J.L. Induction of antiviral antibodies by DNA immunization requires neither perforin-mediated nor CD8(+)-T-cell-mediated lysis of antigen-expressing cells. J. Virol. 73 (1999) 7870-7873
16. Michel M.L., Davis H.L., Schleef M., Mancini M., Tiollais P., and Whalen R.G. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5307-5311
17. Thomas M., Pim D., and Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18 (1999) 7690-7700 [Review]
18. Vousden K.H., Doniger J., DiPaolo J.A., and Lowy D.R. The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res. 3 (1988) 167-175
19. Donnelly J.J., Ulmer J.B., Shiver J.W., and Liu M.A. DNA vaccines. Annu. Rev. Immunol. 15 (1997) 617-648
20. Cheung Y.K., Cheng S.C., Sin F.W., and Xie Y. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine 23 (2004) 629-638
21. Liu W.J., Gao F., Zhao K.N., Zhao W., Fernando G.J., Thomas R., et al. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity. Virology 301 (2002) 43-52
22. Steinberg T., Ohlschlager P., Sehr P., Osen W., and Gissmann L. Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. Vaccine 23 (2005) 149-157
23. Kim J.W., Hung C.F., Juang J., He L., Kim T.W., Armstrong D.K., et al. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. 11 (2004) 1011-1018
24. Foster S.A., Demers G.W., Etscheid B.G., and Galloway D.A. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol. 68 (1994) 5698-5705
25. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23 (1993) 2242-2249
26. Comerford S.A., McCance D.J., Dougan G., and Tite J.P. Identification. J. Virol. 65 (1991) 4681-4690
27. Shi W., Bu P., Liu J., Polack A., Fisher S., and Qiao L. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J. Virol. 73 (1999) 7877-7881
28. York I.A., Goldberg A.L., Mo X.Y., and Rock K.L. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol. Rev. 172 (1999) 49-66
29. Yewdell J., Anton L.C., Bacik I., Schubert U., Snyder H.L., and Bennink J.R. Generating MHC class I ligands from viral gene products. Immunol. Rev. 172 (1999) 97-108
30. Yewdell J.W., and Bennink J.R. Mechanisms of viral interference with MHC class I antigen processing and presentation. Annu. Rev. Cell Dev. Biol. 15 (1999) 579-606
31. Yewdell J.W., and Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17 (1999) 51-88
32. Niedermann G., Geier E., Lucchiari-Hartz M., Hitziger N., Ramsperger A., and Eichmann K. The specificity of proteasomes: impact on MHC class I processing and presentation of antigens. Immunol. Rev. 172 (1999) 29-48
33. Rodriguez F., Zhang J., and Whitton J.L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71 (1997) 8497-8503
34. Tobery T.W., and Siliciano R.F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 185 (1997) 909-920